hematopoietic system
• in the bone marrow of tamoxifen-treated mice
|
• tamoxifen-treated mice exhibit an increase in the percentage of circulating neutrophils compared with wild-type mice
|
• tamoxifen-treated mice exhibit a reduction in long term hematopoietic stem cells compared with wild-type mice
|
• tamoxifen-treated mice exhibit an increase in LSK cells in the bone marrow and peripheral blood compared with wild-type mice
• tamoxifen-treated mice exhibit a 5-fold and 15-fold increase in LSK cells and colony-forming unit cells, respectively, in the spleen compared with wild-type mice
• tamoxifen-treated mice exhibit an increased in hematopoietic progenitors compared with wild-type mice
|
• in a 5-fluorouracil myelosuppression model, tamoxifen-treated mice exhibit increased survival and faster hematologic recovery with less obvious bone marrow regeneration along the endosteal surface and ectopic regeneration in the perisinusoidal space compared with wild-type mice
|
• tamoxifen-treated mice exhibit hyperproliferation and reduced quiescence of hematopoietic stem/progenitor cells compared with wild-type mice
|
immune system
• in the bone marrow of tamoxifen-treated mice
|
• tamoxifen-treated mice exhibit an increase in the percentage of circulating neutrophils compared with wild-type mice
|